ImmuPharma plc Stock price

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:02 2024-03-28 pm EDT 5-day change 1st Jan Change
2.125 GBX -2.52% Intraday chart for ImmuPharma plc +13.33% +27.47%
Sales 2021 118K 149K Sales 2022 - Capitalization 6.13M 7.74M
Net income 2021 -8M -10.1M Net income 2022 -3M -3.79M EV / Sales 2021 126 x
Net cash position 2021 1.65M 2.08M Net cash position 2022 668K 843K EV / Sales 2022 -
P/E ratio 2021
-2.03 x
P/E ratio 2022
-1.46 x
Employees 13
Yield 2021 *
-
Yield 2022
-
Free-Float 55.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.52%
1 week+13.33%
Current month+96.76%
1 month+92.31%
3 months+25.59%
6 months+16.95%
Current year+27.47%
More quotes
1 week
1.71
Extreme 1.705
3.00
1 month
0.82
Extreme 0.822
3.00
Current year
0.82
Extreme 0.822
3.00
1 year
0.82
Extreme 0.822
3.80
3 years
0.82
Extreme 0.822
10.90
5 years
0.82
Extreme 0.822
32.20
10 years
0.82
Extreme 0.822
193.74
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 15-09-29
Chief Operating Officer 60 20-10-31
Director/Board Member 57 12-02-28
Members of the board TitleAgeSince
Chief Executive Officer 68 15-09-29
Chief Operating Officer 60 20-10-31
Director/Board Member 57 12-02-28
More insiders
Date Price Change Volume
24-03-28 2.125 -2.52% 2 354 091
24-03-27 2.18 -15.18% 1,900,622
24-03-26 2.57 +14.73% 5,612,234
24-03-25 2.24 +16.36% 21,295,760
24-03-22 1.925 +8.33% 2,213,747

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity and inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock ImmuPharma plc - London S.E.